Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.
Revenue (Most Recent Fiscal Year) | $160.95M |
Net Income (Most Recent Fiscal Year) | $14.46M |
PE Ratio (Current Year Earnings Estimate) | 22.71 |
PE Ratio (Trailing 12 Months) | 23.69 |
PEG Ratio (Long Term Growth Estimate) | 0.91 |
Price to Sales Ratio (Trailing 12 Months) | 2.36 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.57 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 13.97 |
Pre-Tax Margin (Trailing 12 Months) | 10.47% |
Net Margin (Trailing 12 Months) | 9.60% |
Return on Equity (Trailing 12 Months) | 6.31% |
Return on Assets (Trailing 12 Months) | 4.43% |
Current Ratio (Most Recent Fiscal Quarter) | 3.30 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.93 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 1.21 |
Book Value per Share (Most Recent Fiscal Quarter) | $4.38 |
Earnings per Share (Most Recent Fiscal Quarter) | $0.07 |
Earnings per Share (Most Recent Fiscal Year) | $0.25 |
Diluted Earnings per Share (Trailing 12 Months) | $0.29 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Common Shares Outstanding | 57.48M |
Free Float | 36.73M |
Market Capitalization | $394.88M |
Average Volume (Last 20 Days) | 0.08M |
Beta (Past 60 Months) | 0.94 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 36.10% |
Percentage Held By Institutions (Latest 13F Reports) | 20.38% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |